神经肿瘤学：胶质瘤患者的新希望。 - Suppr

Suppr

超能文献

Neuro-oncology: new hope for patients with gliomas.

作者信息

Deangelis Lisa M

机构信息

Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Lancet Neurol. 2010 Jan;9(1):17-8. doi: 10.1016/S1474-4422(09)70326-6.

DOI:10.1016/S1474-4422(09)70326-6

PMID:20083029

Abstract

摘要

相似文献

Neuro-oncology: new hope for patients with gliomas.

Lancet Neurol. 2010 Jan;9(1):17-8. doi: 10.1016/S1474-4422(09)70326-6.

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.

Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.

IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?

Oncologist. 2010;15(2):196-9. doi: 10.1634/theoncologist.2009-0218. Epub 2010 Feb 4.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27.

Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.

Neuro Oncol. 2023 Jan 5;25(1):26-27. doi: 10.1093/neuonc/noac227.

What do we know about IDH1/2 mutations so far, and how do we use it?

Acta Neuropathol. 2013 May;125(5):621-36. doi: 10.1007/s00401-013-1106-9. Epub 2013 Mar 20.

From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.

World Neurosurg. 2010 Apr;73(4):234-6. doi: 10.1016/j.wneu.2010.02.050.

On high-risk, low-grade glioma: What distinguishes high from low?

Cancer. 2019 Jan 15;125(2):174-176. doi: 10.1002/cncr.31834. Epub 2018 Dec 4.

Neuro-oncology Treatment Strategies for Primary Glial Tumors.

Semin Neurol. 2023 Dec;43(6):889-896. doi: 10.1055/s-0043-1776764. Epub 2023 Dec 14.

引用本文的文献

Brain tumor stem cells: the cancer stem cell hypothesis writ large.

Mol Oncol. 2010 Oct;4(5):420-30. doi: 10.1016/j.molonc.2010.08.001. Epub 2010 Aug 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Neuro-oncology: new hope for patients with gliomas.

Lancet Neurol. 2010 Jan;9(1):17-8. doi: 10.1016/S1474-4422(09)70326-6.

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.

Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.

IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?

Oncologist. 2010;15(2):196-9. doi: 10.1634/theoncologist.2009-0218. Epub 2010 Feb 4.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27.

Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.

Neuro Oncol. 2023 Jan 5;25(1):26-27. doi: 10.1093/neuonc/noac227.

What do we know about IDH1/2 mutations so far, and how do we use it?

Acta Neuropathol. 2013 May;125(5):621-36. doi: 10.1007/s00401-013-1106-9. Epub 2013 Mar 20.

From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.

World Neurosurg. 2010 Apr;73(4):234-6. doi: 10.1016/j.wneu.2010.02.050.

On high-risk, low-grade glioma: What distinguishes high from low?

Cancer. 2019 Jan 15;125(2):174-176. doi: 10.1002/cncr.31834. Epub 2018 Dec 4.

Neuro-oncology Treatment Strategies for Primary Glial Tumors.

Semin Neurol. 2023 Dec;43(6):889-896. doi: 10.1055/s-0043-1776764. Epub 2023 Dec 14.

引用本文的文献

Brain tumor stem cells: the cancer stem cell hypothesis writ large.

Mol Oncol. 2010 Oct;4(5):420-30. doi: 10.1016/j.molonc.2010.08.001. Epub 2010 Aug 10.